All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
35 results for "Cancer" and "Prostate and Urologic Cancers" and "Other Blood Related"
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3-zeta; and 4-1BB Signaling Domains in Pediatric and Young Adult Patients with Relapsed and/or Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Phase 1 Study of CAR-20/19-T Cells in Pediatric and Young adult Patients with R/R B Cell ALL
Protocol No
IIT-TALANO-CART-ALL
Sub Category
A Phase 1b/2a, Open-label, Dose-escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
To assess the safety of STI-6129 in patients with relapse refractory (AL) Amyloidosis. To assess the efficacy of STI-6129 in the treatment of patients with R/R systemic AL Amyloidosis.
Protocol No
SORRENTO-STI-6129-001
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant
Phase II/III Study of ALVR105 After Allogeneic Hematopoietic Cell Transplant
Protocol No
ALLOVIR-P-105-202-PREVENTION
Sub Category
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152-ALL
Sub Category
A Randomized 3-arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old with Untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
HLA-Mismatched Unrelated Donor HCT with Post-Transplantation Cyclophosphamide (Access)
Protocol No
NMDP-ACCESS
Sub Category
Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant
AlloVir P-106-001 Study in Patients Developing Respiratory Infections Post HSCT
Protocol No
ALLOVIR-P-106-001-RESP
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
A Phase II Study of CART-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Phase II Study of CART-ddBCMA for the Treatment of Patients with R/R Multiple Myeloma
Protocol No
ARCELLX-ARC-112A-CART-DDBCMA
Sub Category
Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
Phase I Trial of CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-TRIPLE-CAR20-19-22
Sub Category
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
BCMA Directed CAR-T Cells in Relapsed And Or Refractory Multiple Myeloma
Protocol No
NOVARTIS-ADPT07A12101BCMA-CART
Sub Category
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Protocol No
PROTHENA-NEOD001-301
Sub Category
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti-CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Sub Category
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Ravulizumab in TMA after HSCT
Protocol No
ALEXION-ALXN1210-TMA-313
Sub Category
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
Protocol No
ARCELLX-ACLX-001-DDBCMA
Sub Category
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
Clinical Trial to Evaluate CT053 in Patients with R/R-MM (LUMMICAR Study 2)
Protocol No
CARSGEN-CT053-MM-02
Sub Category
A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Protocol No
FATE-FT576-101-MM
Sub Category
A Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients with Virus-Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Cell Transplant
Trial of Viralym-M (ALVR105) for Patients With Virus-Associated Hemorrhagic Cystitis after allo-HCT
Protocol No
ALLOVIR-AVM-003-HC
Sub Category
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Protocol No
HJKC3-0002
Sub Category
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1- Antitrypsin (AAT) Combined with Corticosteroids vs. Corticosteroids Alone for the Treatment of High-Risk Acute Graft-versus-Host-Disease (GVHD) Following Hematopoietic Stem Cell Transplant
Alpha 1- Antitrypsin Combined with Corticosteroids vs. Corticosteroids Alone for Tx of aGVHD
Protocol No
CTN-1705
Sub Category